- 5. F. T. Kenney, Advances in Enzyme Regulation Vol. 1, p. 137. Pergamon Press, Oxford (1963).
- F. ROSEN and C. A. NICHOL, Vitamins and Hormones Vol. 21, p. 166. Academic Press, New York (1963).
- A. W. LAJKO, Antibiotiki 7, 601 (1962).
- 8. G. G. GAUZE, N. P. LOSHKAREVA and Yu. W. DUDNIK, Antibiotiki 10, 307 (1965).
- 9. G. G. GAUZE and N. P. LOSHKAREVA, Voprosi Med. Khimii 11, 79 (1965).
- 10. G. F GAUZE, in *Antibiotics*—1. *Mechanism of action* (Eds. D. GOTTLIEB and P. D. SHAW) (Russ. trans., "Mir" Publishing House), Vol. 1, p. 238. Mir, Moscow (1969).
- 11. J. Fok and M. WARING, Molec. Pharmac. 8, 65 (1972).
- 12. M. J. WARING, J. molec. Biol. 54, 247 (1970).
- 13. O. Greengard and G. Acs., Biochim. biophys. Acta 61, 652 (1962).
- 14. O. GREENGARD, M. A. SMITH and G. Acs, J. biol. Chem. 238, 1548 (1963).
- 15. O. Greengard, Advances in Enzyme Regulation Vol. 2, p. 277. Pergamon Press, Oxford (1964).

Biochemical Pharmacology, Vol. 22, pp. 1529-1531. Pergamon Press, 1973. Printed in Great Britain.

A novel hypoglycemic compound*

(Received 31 July 1972; accepted 23 November 1972)

THE HYPOGLYCEMIC activity of 2-piperazino-4(3H)-quinazolinone monoacetate (referred to as Compound I) on rat and rabbit has been reported.^{1,2} More recently the effect of Compound I has been studied in other species of normal animals and in diabetic rats and monkeys The results obtained are presented in this paper.

Albino rats of the Central Drug Research Institute colony (120–175 g) and the Charles-Foster strain (118–135 g); albino rabbits (1·2-1·5 kg) and guinea pigs (400–600 g) of the Central Drug Research Institute colony; mongrel dogs (6–11 kg) and rhesus monkeys (*Macaca mulatta*) (4–6 kg) were used in these experiments.

Compound I was administered orally as a solution in distilled water, in doses from 10 to 100 mg/kg body wt as shown in the tables. Control animals received an equal volume of the vehicle.

Alloxan, obtained from British Drug Houses, was administered to albino rats and monkeys. Administration of 1 to 4 units of Plain and PZ insulin per animal were needed to override the initial phase of hyperglycemia and acidosis for about 3 weeks. Albino rats after fasting had a blood sugar level greater than 400 mg per cent and monkeys had levels greater than 300 mg per cent. Only animals in this range were selected. Another group of albino rats were 95 per cent pancreatectomized by the method of Scow.³ After recovery (28 days) they received an intramuscular injection of hydrocortisone (Calbiochem) (5 mg/rat/day) in 10 per cent ethyl-alcohol for 4-6 days to produce diabetes, characterized by a fasting blood sugar level greater than 200 mg per cent on 2 successive days.

The animals were fasted overnight, water being allowed *ad lib*. Blood from a vein was collected from the animals prior to administration of Compound I and later at various intervals. Blood sugar was estimated according to Somogyi's method as modified by Nelson.⁴

It can be seen from Table 1, that Compound I has a lowering effect on the blood sugar in albino rats, rabbits and dogs. However, the blood sugar of the monkey increases slightly. The blood sugar levels of guinea pigs were not altered.

From Table 2, it is clear that Compound I is capable of lowering the blood sugar of hydrocortisone treated pancreatectomized (max = 51 per cent) rats; whereas it has just a slight effect (max = 6 per cent) on alloxan-treated rats. Compound I lowers blood sugar levels of alloxan-treated monkeys, the maximum effect being 51 per cent, as is evident from Table 2. Thus the hypoglycemic character of Compound I has been confirmed in different species of normal and diabetic animals. It can lower blood sugar considerably when given orally to hydrocortisone-treated pancreatectomized albino rats

* Communication No. 1720 from Central Drug Research Institute, Lucknow, India.

An abstract of the paper consisting of a part of the data was accepted for presentation in the 7th Congress of the International Diabetes Federation at Buenos Aires in August 1970.

as well as alloxan-treated monkeys. Failure of the compound to evoke hypoglycemia in dogs and monkeys is unexplained.

Chronic toxicity of the compound and its mode of action is being currently investigated.

Acknowledgements—The author's sincere thanks are due to Drs. C. M. Gupta, A. P. Bhaduri and N. M. Khanna for the synthesis and generous supply of Compound I. The technical assistance of Messrs. M. A. Hai, H. M. Chakravarty, Ramanand and Raj Kumar is greatly appreciated. Thanks are also due to Dr. S. S. Mukerjee for his assistance in the alloxan treatment of monkeys.

Experimental Medicine Division, Central Drug Research Institute, Post Box No. 173 Lucknow, India SURATH K. MUKHERJEE

REFERENCES

- C. M. GUPTA, S. T. HUSAIN, A. P. BHADURI, N. M. KHANNA and S. K. MUKHERJEE, Nature 223, 524 (1969).
- 2. C. M. GUPTA, A. P. BHADURI, N. M. KHANNA and S. K. MUKHERJEE, Ind. J. Chem. 9, 201 (1971).
- 3. R. O. Scow, Endocrinology 60, 359 (1957).
- 4. N. NELSON, J. biol. Chem. 153, 375 (1944).

TABLE 1. SHOWING THE EFFECT OF COMPOUND I IN DIFFERENT SPECIES OF NORMAL ANIMALS

	Species	No. animals	Dose (mg/kg)	Time after dosing (hr)	Change in blood sugar from initial (%)
1	Albino rat (C.F. strain)	6	75	2	(-) 57
2	Albino rat (CDRI colony)	6	0	2	0
3	Albino rat (CDRI colony)	10	75	2	(-) 63
4	Albino rat (CDRI colony)	26	50	2	(-) 52
5	Albino rat (CDRI colony)	12	35	2	(-) 54
6	Albino rat (CDRI colony)	18	25	2	() 46
7	Albino rabbit (CDRI colony)	4	0	2	(+) 6
8	Albino rat (CDRI colony)	7	100	2	(-) 27
9	Guinea pig	4	100	2	0
10	Dog (mongrel)	2	0	2 ½ ½ 1	0
11	Dog (mongrel)	3	50	1/2	(—) 15
12	Dog (mongrel)	2	20	1	() 15
13	Dog (mongrel)	2 2	10	1	() 19
14	Rhesus monkey (Macaca mulatta)	2	0	2–4	(+) 6
15	Rhesus monkey (Macaca mulatta)	3	100	2	(+) 20
16	Rhesus monkey (Macaca mulatta)	2	60	2	(+) 20
17	Rhesus monkey (Macaca mulatta)	2	20	2	(+) 14·5

⁽⁻⁾ Fall in blood sugar.

⁽⁺⁾ Rise in blood sugar.

Table 2. Showing the effect of Compound I, in hyperglycemic albino rat and rhesus monkey

	sting after 1 hr after 2 hr after 4 hr	22.3 (4) 397 \pm 40.81 (4) 390 \pm 31.01 (4)	392 ± 26.17 (6)		*116 \pm 16·30 (6)	$333 \pm 27 \cdot 2 (3)$ $320 \pm 40 \cdot 3 (3)$	$346 \pm 45.7 (3)$ *286 $\pm 25.0 (3)$	
	(g) Fasting	415 ± 22·3 (4)				$340 \pm 20.4 (3)$		
2	(mg/kg)		90		100		20	
	Drug	Ē			1		-	
	Nature of diabetes	Ailoxan	Alloxan	Pancreatectomized	ingurocornisone treated	Alloxan	Alloxan	
	Species	Albino rat	Albino rat	Albino rat		Rhesus monkey	Rhesus monkey	

Figures in parentheses indicate number of observations. • Significant at 5 per cent level compared to fasting value. Values indicate Mean \pm S.E.